Aarti industries share price

In August last year, Aarti Industries announced a plan to separate its speciality chemicals business (to operate under Aarti Industries Limited – AIL) and its pharma business (Aarti Pharmalabs Limited – APL), with October 20, 2022, as the record date for the demerger. Accordingly, the pharma business (22 per cent of FY22 revenues) will be demerged into APL, and the original speciality chemicals business will continue under AIL. As of the record date, all shareholders will receive one equity share of APL for every four shares of AIL. The demerger allows the two entities, with different end-markets and capital funding requirements, to streamline and improve their respective operations. The proposed demerger was one of the reasons for the ‘accumulate’ recommendation given in our bl.portfolio edition dated August 21. Trading at ₹690, the 7 per cent decline recorded by AIL shares versus yesterday is due to the upcoming record date tomorrow; only shareholders who had bought AIL till yesterday can receive APL shares. Theoretically, while shareholders could have expected a 10-15 per cent decline (equal to the value of the new business — APL, being demerged), the actual decline is lower, reflecting investor perception of the benefits of value unlocking from the demerger. The new shares of APL will be listed by mid-December, according to the company. Aarti Pharma Labs APL operates in three segments — active pharmaceutical ingredient (API), intermediaries, and manufacture of xanthine...

Aarti Industries Limited is engaged in manufacturing and dealing in specialty chemicals and pharmaceuticals. The Company operates through two segments as Specialty Chemicals and Pharmaceuticals. Its Specialty Chemicals segment serves polymer and additives; agrochemicals and intermediates; dyes, pigments, paints, and printing inks; pharma intermediates, and fuel additives, rubber chemicals, and resins markets. Its Pharmaceuticals segment serves active pharmaceutical ingredients and intermediates for innovators and generic companies. The Company is integrated across over 200 products. Its products include Benzene products, Toluene products, Sulphuric Acid products, and Other specialty chemicals. ;

Sales 2023 67886M 828M 828M Net income 2023 5324M 64,9M 64,9M Net Debt 2023 25214M 308M 308M P/E ratio 2023 35,4x Yield 2023 0,40% Sales 2024 76669M 935M 935M Net income 2024 6047M 73,8M 73,8M Net Debt 2024 35001M 427M 427M P/E ratio 2024 31,2x Yield 2024 0,50% Capitalization 189B 2300M 2300M EV / Sales 2023 3,15x EV / Sales 2024 2,92x Nbr of Employees 7 700 Free-Float 54,8% More Financials Company Aarti Industries Limited is engaged in manufacturing and dealing in specialty chemicals and pharmaceuticals. The Company operates through two segments as Specialty Chemicals and Pharmaceuticals. Its Specialty Chemicals segment serves polymer and additives; agrochemicals and intermediates; dyes, pigments, paints, and printing inks; pharma intermediates, and fuel additives, rubber chemicals, and resins markets. Its...

It is hard to get excited after looking at Aarti Industries' (NSE:AARTIIND) recent performance, when its stock has declined 2.9% over the past three months. However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with future market price movements. Particularly, we will be paying attention to Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. Simply put, it is used to assess the profitability of a company in relation to its equity capital. How Do You Calculate Return On Equity? The formula for return on equity is: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Aarti Industries is: 11% = ₹5.5b ÷ ₹49b (Based on the trailing twelve months to March 2023). The 'return' is the profit over the last twelve months. One way to conceptualize this is that for each ₹1 of shareholders' capital it has, the company made ₹0.11 in profit. What Has ROE Got To Do With Earnings Growth? So far, we've learned that ROE is a measure of a company's profitability. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company’s earnings growth potential. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes. A Side By...